Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains

PPARβ/δ governs Wnt signaling and bone turnover.

Carina Scholtysek1, Julia Katzenbeisser, He Fu

  • 1Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nürnberg, Erlangen, Germany.

Nature Medicine
|April 2, 2013

Related Experiment Videos

View abstract on PubMed

Summary

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Pparβ/δ Governs Wnt Signaling And Bone Turnover.
    • This summary is machine-generated.

    Peroxisome proliferator-activated receptor beta/delta (PPARβ/δ) regulates bone turnover by enhancing osteoblast signaling and reducing osteoclast activity. This discovery offers a new therapeutic target for osteoporosis.

    Area of Science:

    • Endocrinology
    • Bone Biology
    • Metabolic Regulation

    Background:

    • Peroxisome proliferator-activated receptors (PPARs) are key metabolic sensors regulating fat and glucose homeostasis.
    • PPARγ is known to regulate bone mass, but the roles of other PPAR subtypes remain unclear.
    • Understanding PPAR subtype involvement in bone homeostasis is crucial for metabolic and bone disease research.

    Purpose of the Study:

    • To investigate the role of PPARβ/δ in bone turnover and its crosstalk with osteoblasts and osteoclasts.
    • To explore PPARβ/δ as a potential therapeutic target for osteoporosis.

    Main Methods:

    • Utilized PPARβ/δ-deficient mice to assess bone homeostasis.
    • Examined Wnt signaling, osteoprotegerin (OPG), and osteoclastogenesis.
    • Employed a mouse model of postmenopausal osteoporosis treated with a PPARβ/δ activator.

    Main Results:

    • PPARβ/δ activation enhanced Wnt signaling and osteoprotegerin (OPG) expression in osteoblasts, inhibiting osteoclastogenesis.
    • PPARβ/δ-deficient mice exhibited reduced Wnt signaling, lower OPG, increased osteoclasts, and osteopenia.
    • Pharmacological PPARβ/δ activation in osteoporosis models normalized the RANKL/OPG ratio and restored bone density.

    Conclusions:

    • PPARβ/δ is a critical regulator of bone turnover, distinct from PPARγ.
    • PPARβ/δ activation promotes osteoblast function and suppresses osteoclast activity.
    • PPARβ/δ represents a promising therapeutic target for treating osteoporosis and related bone disorders.

    Related Experiment Videos